• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13D/A filed by Allurion Technologies Inc.

    7/2/24 5:51:42 PM ET
    $ALUR
    Medical/Dental Instruments
    Health Care
    Get the next $ALUR alert in real time by email
    SC 13D/A 1 p24-2302sc13da.htm ALLURION TECHNOLOGIES INC.

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    SCHEDULE 13D/A
    (Amendment No. 2)

    Under the Securities Exchange Act of 1934

    ALLURION TECHNOLOGIES, INC.

    (formerly known as Allurion Technologies Holdings, Inc.)
    (Name of Issuer)

    Common Stock, par value $0.0001 per share
    (Title of Class of Securities)

    02008G102
    (CUSIP Number)

    RTW Investments, LP
    Attn: Roderick Wong, M.D.
    40 10th Avenue, Floor 7
    New York, New York 10014
    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

    June 28, 2024
    (Date of Event which Requires Filing of this Statement)

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ☐

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    CUSIP No. 02008G10213D/APage 2 of 8 Pages

     

    1.

    Name of Reporting Person

    RTW Investments, LP

    2. Check the Appropriate Box if a Member of a Group

    (a) ¨

    (b) ¨

    3. SEC Use Only
    4.

    Source of Funds (See Instructions)

    AF

    5. Check if Disclosure of Legal Proceeding Is Required Pursuant to Items 2(d) or 2(e) ¨
    6.

    Citizenship or Place of Organization

    Delaware

    Number of Shares Beneficially Owned By Each Reporting Person with 7.

    Sole Voting Power

    0

    8.

    Shared Voting Power

    4,416,587 (including 479,196 Shares issuable upon conversion of the Notes (as defined in Item 4 of the Schedule 13D) and 239,842 Shares issuable upon exercise of Public Warrants (as defined in Item 4 of this Amendment No. 2))*

    9.

    Sole Dispositive Power

    0

    10.

    Shared Dispositive Power

    4,416,587 (including 479,196 Shares issuable upon conversion of the Notes and 239,842 Shares issuable upon exercise of Public Warrants)*

    11.

    Aggregate Amount Beneficially Owned by Each Reporting Person

    4,416,587 (including 479,196 Shares issuable upon conversion of the Notes and 239,842 Shares issuable upon exercise of Public Warrants)*

    12. Check Box if the Aggregate Amount in Row (11) Excludes Certain Shares ¨
    13.

    Percent of Class Represented by Amount in Row (11)

    7.0%*, **

    14.

    Type of Reporting Person

    PN, IA

             

    *The exercise of the Public Warrants reported herein is subject to the Blocker (as defined in Item 4 of this Amendment No. 2) and the percentage set forth in row (13) gives effect to the Blocker. However, rows (8), (10) and (11) show the number of Shares that would be issuable upon the exercise of the Public Warrants in full and does not give effect to the Blocker. Therefore, the actual number of Shares beneficially owned by such Reporting Person, after giving effect to the Blocker, is less than the number of securities reported in rows (8), (10) and (11).

    **Percentage based upon 62,305,245 shares of the Company’s Common Stock reported to be outstanding in the Company’s Prospectus filed pursuant to Rule 424(b)(4) with the Securities and Exchange Commission on June 28, 2024, after giving effect to the completion of the public offering and private placement described under Item 4 below, and assumes the conversion of the Notes up to the Conversion Cap (as defined in Item 4 of the Schedule 13D) and the exercise of the Public Warrants subject to the Blocker (as defined in Item 4 of this Amendment No. 2) and no conversion of the Series A Preferred Stock or exercise of the Private Warrants.

     

    CUSIP No. 02008G10213D/APage 3 of 8 Pages

     

    1.

    Name of Reporting Person

    Roderick Wong, M.D.

    2. Check the Appropriate Box if a Member of a Group

    (a) ¨

    (b) ¨

    3. SEC Use Only
    4.

    Source of Funds (See Instructions)

    AF

    5. Check if Disclosure of Legal Proceeding Is Required Pursuant to Items 2(d) or 2(e)  ☐
    6.

    Citizenship or Place of Organization

    United States of America

    Number of Shares Beneficially Owned By Each Reporting Person with 7.

    Sole Voting Power

    0

    8.

    Shared Voting Power

    4,416,587 (including 479,196 Shares issuable upon conversion of the Notes and 239,842 Shares issuable upon exercise of Public Warrants)*

    9.

    Sole Dispositive Power

    0

    10.

    Shared Dispositive Power

    4,416,587 (including 479,196 Shares issuable upon conversion of the Notes and 239,842 Shares issuable upon exercise of Public Warrants)*

    11.

    Aggregate Amount Beneficially Owned by Each Reporting Person

    4,416,587 (including 479,196 Shares issuable upon conversion of the Notes and 239,842 Shares issuable upon exercise of Public Warrants)*

    12. Check Box if the Aggregate Amount in Row (11) Excludes Certain Shares  ¨
    13.

    Percent of Class Represented by Amount in Row (11)

    7.0%*, **

    14.

    Type of Reporting Person

    IN, HC

             

    *The exercise of the Public Warrants reported herein is subject to the Blocker and the percentage set forth in row (13) gives effect to the Blocker. However, rows (8), (10) and (11) show the number of Shares that would be issuable upon the exercise of the Public Warrants in full and does not give effect to the Blocker. Therefore, the actual number of Shares beneficially owned by such Reporting Person, after giving effect to the Blocker, is less than the number of securities reported in rows (8), (10) and (11).

    ** Percentage based upon 62,305,245 shares of the Company’s Common Stock reported to be outstanding in the Company’s Prospectus filed pursuant to Rule 424(b)(4) with the Securities and Exchange Commission on June 28, 2024, after giving effect to the completion of the public offering and private placement described under Item 4 below, and assumes the conversion of the Notes up to the Conversion Cap (as defined below) and the exercise of the Public Warrants subject to the Blocker and no conversion of the Series A Preferred Stock or exercise of the Private Warrants.

     

    CUSIP No. 02008G10213D/APage 4 of 8 Pages

     

    The following constitutes Amendment No. 2 (“Amendment No. 2”) to the initial statement on Schedule 13D, filed on August 11, 2023 (the “Initial Schedule 13D”), as amended by Amendment No. 1 filed on April 17, 2024 (“Amendment No. 1”) by the undersigned. This Amendment No. 2 amends the Initial Schedule 13D and Amendment No. 1 as specifically set forth herein (the Initial Schedule 13D as amended by Amendment No. 1 and this Amendment No. 2, the “Schedule 13D”). Capitalized terms used in this Amendment No. 2 and not otherwise defined herein have the meanings given to them in the Schedule 13D.

    Item 3. Source and Amount of Funds or Other Consideration.

    Item 3 of the Schedule 13D is hereby amended to add the following:

    The source of funds used for the purchase of the Shares, the Public Warrants, the Series A Preferred Stock and the Private Warrants (each as defined below and collectively the “Securities”) was the working capital of the RTW Funds. The aggregate purchase price of 239,842 Shares, Public Warrants to purchase 239,842 Shares, 2,260,159 shares of Series A Preferred Stock and Private Warrants to purchase 2,260,159 Shares was $3.0 million.

    Item 4. Purpose of Transaction.

    Item 4 of the Schedule 13D is hereby amended to add the following:

    The RTW Funds invested an aggregate of $3.0 million in (i) the Company’s public offering of Shares and warrants to purchase Shares (the “Public Warrants”) pursuant to the Company’s Registration Statement on Form S-1 (File number 333-280466) initially filed with the Securities and Exchange Commission on June 26, 2024, as amended and (ii) a concurrent private placement of a newly-created series of preferred stock, Series A convertible preferred stock (the “Series A Preferred Stock”) and accompanying private placement warrants.

     

    The RTW Funds are deemed to be related parties under New York Stock Exchange listing rules, which require stockholder approval for issuances of Shares in an amount greater than 1% of the Shares currently outstanding. Accordingly, in lieu of Shares, to the extent that the investment of $3.0 million by the RTW Funds in the Company’s public offering at the Public Offering Price (as defined below) would result in the issuance of greater than 1% of the Shares currently outstanding to the RTW Funds, the RTW Funds acquired shares of Series A Preferred Stock.

    Accordingly, the RTW Funds (i) acquired 239,842 Shares and Public Warrants to purchase 239,842 Shares at $1.20 per share of Common Stock and associated Public Warrant (the “Public Offering Price”) in the Company’s public offering on the same terms and conditions as the other Shares and Public Warrants sold in the public offering and (ii) on June 28, 2024, the RTW Funds entered into a subscription agreement (the “Subscription Agreement”) with Company pursuant to which the RTW Funds agreed to purchase 2,260,159 shares of Series A Preferred Stock, and accompanying private placement warrants to purchase 2,260,159 Shares (the “Private Warrants”) in a concurrent private placement. The terms of the Series A Preferred Stock are set forth in a Certificate of Designations filed by the Company (the “Certificate of Designations”). The purchase price for the Series A Preferred Stock and Private Warrants, purchased together, is $1.20 per share of Series A Preferred Stock and associated Private Warrant, and the Private Warrants have an exercise price of $1.20 per share.

     

    CUSIP No. 02008G10213D/APage 5 of 8 Pages

    A holder (together with its affiliates) may not exercise any portion of the Public Warrants or Private Warrants to the extent that such holder would own more than 4.99% (or, at the election of the purchaser, 9.99%) of the Company’s outstanding Shares immediately after exercise of such warrants, except that, upon at least 61 days’ prior notice from such holder to the Company, such holder may increase the amount of beneficial ownership of outstanding Shares after exercising such holder’s warrants (the “Blocker”). The Public Warrants and the Private Warrants held by the RTW Funds are subject to a Blocker, which is currently set at 4.99% and can be increased to 9.99% upon 61 days’ prior notice and accordingly, the Reporting Persons have included the Shares issuable upon exercise of Public Warrants up to 9.99% of the outstanding Shares in their beneficial ownership. Until Stockholder Approval, the Private Warrants are not exercisable.

     

    The public offering and the concurrent private placement were consummated on July 1, 2024.

    Pursuant to the Subscription Agreement, the Company is required to include a proposal in its definitive proxy statement on Schedule 14A seeking stockholder approval of the conversion of the Series A Preferred Stock and the exercise of the Private Warrants (the “Stockholder Approval”) no later than December 31, 2025, and if the Company does not obtain Stockholder Approval at such meeting, it shall call a special meeting of stockholders each 90-day period thereafter at least two times, and thereafter at each subsequent annual meeting until Stockholder Approval is obtained or the shares of Series A Preferred Stock and Private Warrants are no longer outstanding. Each share of Series A Preferred Stock will automatically convert into one share of Common Stock (or equivalent pre-funded warrants, and subject to customary anti-dilution provisions) upon receipt of the Stockholder Approval. The Private Warrants are not exercisable prior to Stockholder Approval.

    The shares of Series A Preferred Stock have no voting rights except as required by law. The Series A Preferred Stock ranks (i) junior to any class or series of preferred stock of the Company hereafter created, (ii) junior to any senior secured debt obligations and (iii) pari passu with the Common Stock as to distributions of assets upon liquidation, dissolution or winding up of the Company, whether voluntarily or involuntarily.

    Each share of Series A Preferred Stock outstanding on December 31, 2026 (the “Redemption Date”) shall, except to the extent prohibited by Delaware law governing distributions to stockholders, be redeemed by the Company for cash at a redemption price equal to the volume-weighted average price per share of the Common Stock during the twenty (20) consecutive Trading Day period ending and including the trading day immediately preceding the Redemption Date (the “Redemption Price”). If the shares of Series A Preferred Stock are redeemed, the Company must offer to repurchase the Private Warrants at a price per share of underlying Common Stock equal to the Redemption Price minus the exercise price of the Private Warrants.

     

    CUSIP No. 02008G10213D/APage 6 of 8 Pages

      

    The foregoing descriptions of the Subscription Agreement, the Certificate of Designations, the Public Warrant and the Private Warrant are not complete and are qualified in their entirety by reference to the complete text of the Subscription Agreement, which is filed as Exhibit 99.14 to the Schedule 13D, the Certificate of Designations, which is filed as Exhibit 99.15 to the Schedule 13D, the Public Warrant, which is filed as Exhibit 99.16 to the Schedule 13D, and the Private Warrant, which is filed as Exhibit 99.17 to the Schedule 13D.

    Item 5. Interest in Securities of the Issuer.

    Item 5 is hereby amended and restated as follows:

    (a) The aggregate percentage of Shares reported to be beneficially owned by the Reporting Persons is based upon 62,305,245 shares of the Company’s Common Stock reported to be outstanding in the Company’s Prospectus filed pursuant to Rule 424(b)(4) with the Securities and Exchange Commission on June 28, 2024, after giving effect to the completion of the public offering and private placement described under Item 4, and assumes the conversion of the Notes up to the Conversion Cap and the exercise of the Public Warrants subject to the Blocker and no conversion of the Series A Preferred Stock or exercise of the Private Warrants.

    (b) See rows (7) through (10) of the cover page to this Amendment No. 2 for the number of Shares as to which each Reporting Person has the sole or shared power to vote or direct the vote and sole or shared power to dispose or to direct the disposition.

    (c) The Reporting Persons did not effect any transactions with respect to the Shares during the past sixty (60) days other than as reported in Item 4.

    (d) No person, other than the Reporting Persons and the RTW Funds, has the right to receive or the power to direct the receipt of dividends or proceeds of sale of the Shares reported herein.

    (e) Not applicable.

    Item 6.Contracts, Arrangements, Understandings Or Relationships With Respect To Securities Of The Issuer

    The Reporting Persons’ response to Item 4 is incorporated by reference into this Item 6.

     

    CUSIP No. 02008G10213D/APage 7 of 8 Pages

     

    Item 7. Materials to be Filed as Exhibits.

    Item 7 of the Schedule 13D is hereby amended to add the following:

    99.14 Subscription Agreement, dated as of June 28, 2024, by and among the Company and the RTW Funds (incorporated herein by reference to Exhibit 10.1 to the Current Report on Form 8-K filed by the Company with the Securities and Exchange Commission on July 1, 2024).

    99.15 Certificate of Designations for the Series A Preferred Stock of the Company (incorporated herein by reference to Exhibit 3.1 to the Current Report on Form 8-K filed by the Company with the Securities and Exchange Commission on July 1, 2024).

    99.16 Form of Public Warrant (incorporated herein by reference to Exhibit 4.1 to the Current Report on Form 8-K filed by the Company with the Securities and Exchange Commission on July 1, 2024).

    99.17 Form of Private Placement Warrant (incorporated herein by reference to Exhibit 4.2 to the Current Report on Form 8-K filed by the Company with the Securities and Exchange Commission on July 1, 2024).

     

     

    CUSIP No. 02008G10213D/APage 8 of 8 Pages

    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete, and correct.

    Date: July 2, 2024

      RTW INVESTMENTS, LP
       
      By: /s/ Roderick Wong, M.D.
      Name: Roderick Wong, M.D.
      Title: Managing Partner
       
      /s/ Roderick Wong, M.D.
      RODERICK WONG, M.D.

     

     

    Get the next $ALUR alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $ALUR

    DatePrice TargetRatingAnalyst
    11/14/2024Buy → Neutral
    Chardan Capital Markets
    10/2/2024$2.00Buy
    TD Cowen
    9/6/2024$2.00Buy
    ROTH MKM
    2/9/2024$5.00Buy
    Jefferies
    More analyst ratings

    $ALUR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Executive Officer Gaur Shantanu bought $24,484 worth of shares (8,000 units at $3.06), increasing direct ownership by 100% to 16,000 units (SEC Form 4)

      4 - ALLURION TECHNOLOGIES, INC. (0001964979) (Issuer)

      5/21/25 4:15:08 PM ET
      $ALUR
      Medical/Dental Instruments
      Health Care
    • Chief Executive Officer Gaur Shantanu bought $26,800 worth of shares (8,000 units at $3.35) (SEC Form 4)

      4 - ALLURION TECHNOLOGIES, INC. (0001964979) (Issuer)

      4/1/25 4:15:07 PM ET
      $ALUR
      Medical/Dental Instruments
      Health Care

    $ALUR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Allurion Announces Submission of PMA to FDA and Additional Analyses From Pivotal AUDACITY Study That Meet Both Endpoints

      Fourth and final module of the PMA submitted in June Supportive analyses included in final module of the PMA meet both of the pre-specified co-primary endpoints in the AUDACITY Study Allurion Technologies, Inc. (NYSE:ALUR), a pioneer in metabolically healthy weight loss, today announced submission of the fourth and final module of the Pre-Market Approval (PMA) application to the Food & Drug Administration (FDA) and additional, supportive analyses from the AUDACITY Study that meet both of the pre-specified co-primary endpoints. Topline results announced previously showed that the AUDACITY Study met its first co-primary endpoint related to responder rate at 48 weeks. Allurion Balloon su

      7/7/25 8:00:00 AM ET
      $ALUR
      Medical/Dental Instruments
      Health Care
    • Allurion Announces Findings from New Studies on Muscle Mass Maintenance in Nearly 20,000 Patients and Four-Year Weight Loss Outcomes at the 2025 Annual Meeting of the ASMBS

      Findings from two abstracts presented at the American Society for Metabolic & Bariatric Surgery (ASMBS) 2025 Annual Meeting reinforce the role of the AI-powered Allurion Program in delivering metabolically healthy weight loss Real-world experience in nearly 20,000 patients with the Allurion Program confirms significant fat loss while increasing lean body and muscle mass In one of the longest real-world studies of its kind, patients who followed the Allurion Program for four years maintained, on average, 89% of the weight lost during balloon therapy Allurion Technologies, Inc. (NYSE:ALUR), a pioneer in metabolically healthy weight loss, today presented two new abstracts at the Amer

      6/17/25 8:00:00 AM ET
      $ALUR
      Medical/Dental Instruments
      Health Care
    • Allurion to Present at Jefferies Global Healthcare Conference

      Allurion Technologies, Inc. ("Allurion" or the "Company") (NYSE:ALUR), a pioneer in metabolically healthy weight loss, today announced that Dr. Shantanu Gaur, Founder and Chief Executive Officer, will present at the upcoming Jefferies Global Healthcare Conference in New York. The live presentation will take place on Wednesday, June 4 at 3:45 p.m. ET. A webcast of the presentation will be available in the Events & Presentations section of Allurion's investor relations website. About Allurion Allurion is a pioneer in metabolically healthy weight loss. The Allurion Program is a weight-loss platform that combines the Allurion Gastric Balloon, the world's first and only swallowable, proced

      5/29/25 4:05:00 PM ET
      $ALUR
      Medical/Dental Instruments
      Health Care

    $ALUR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Executive Officer Gaur Shantanu bought $24,484 worth of shares (8,000 units at $3.06), increasing direct ownership by 100% to 16,000 units (SEC Form 4)

      4 - ALLURION TECHNOLOGIES, INC. (0001964979) (Issuer)

      5/21/25 4:15:08 PM ET
      $ALUR
      Medical/Dental Instruments
      Health Care
    • Director Rtw Investments, Lp converted options into 1,492,539 shares (SEC Form 4)

      4 - ALLURION TECHNOLOGIES, INC. (0001964979) (Issuer)

      4/17/25 6:36:58 PM ET
      $ALUR
      Medical/Dental Instruments
      Health Care
    • Chief Executive Officer Gaur Shantanu bought $26,800 worth of shares (8,000 units at $3.35) (SEC Form 4)

      4 - ALLURION TECHNOLOGIES, INC. (0001964979) (Issuer)

      4/1/25 4:15:07 PM ET
      $ALUR
      Medical/Dental Instruments
      Health Care

    $ALUR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Allurion Technologies downgraded by Chardan Capital Markets

      Chardan Capital Markets downgraded Allurion Technologies from Buy to Neutral

      11/14/24 8:29:33 AM ET
      $ALUR
      Medical/Dental Instruments
      Health Care
    • TD Cowen initiated coverage on Allurion Technologies with a new price target

      TD Cowen initiated coverage of Allurion Technologies with a rating of Buy and set a new price target of $2.00

      10/2/24 7:13:57 AM ET
      $ALUR
      Medical/Dental Instruments
      Health Care
    • ROTH MKM initiated coverage on Allurion Technologies with a new price target

      ROTH MKM initiated coverage of Allurion Technologies with a rating of Buy and set a new price target of $2.00

      9/6/24 7:25:38 AM ET
      $ALUR
      Medical/Dental Instruments
      Health Care

    $ALUR
    SEC Filings

    See more
    • SEC Form S-8 filed by Allurion Technologies Inc.

      S-8 - ALLURION TECHNOLOGIES, INC. (0001964979) (Filer)

      6/18/25 5:10:21 PM ET
      $ALUR
      Medical/Dental Instruments
      Health Care
    • SEC Form 424B3 filed by Allurion Technologies Inc.

      424B3 - ALLURION TECHNOLOGIES, INC. (0001964979) (Filer)

      5/20/25 5:04:39 PM ET
      $ALUR
      Medical/Dental Instruments
      Health Care
    • SEC Form 424B3 filed by Allurion Technologies Inc.

      424B3 - ALLURION TECHNOLOGIES, INC. (0001964979) (Filer)

      5/20/25 5:02:23 PM ET
      $ALUR
      Medical/Dental Instruments
      Health Care

    $ALUR
    Leadership Updates

    Live Leadership Updates

    See more
    • Allurion Announces the Appointment of Eli Lilly Veteran, Keith Johns, to Its Board of Directors

      Mr. Johns has worked over two decades bringing leading GLP-1 weight loss drugs and other metabolic drugs to market Allurion Technologies, Inc. (NYSE:ALUR), a company dedicated to ending obesity, today announced the appointment of Keith Johns to its Board of Directors effective September 2, 2024. "We are extremely excited to welcome Keith to the Allurion Board of Directors as we look to capitalize on the significant opportunity in front of us within the fast-growing obesity management space," said Dr. Shantanu Gaur, Allurion's Founder and CEO. "I believe having Keith as a sounding board as we leverage the opportunities created by GLP-1s will be a competitive advantage." Omar Ishrak, Al

      9/3/24 8:00:00 AM ET
      $ALUR
      Medical/Dental Instruments
      Health Care
    • Allurion Announces the Appointment of Adrian Wild as Senior Vice President, International Commercial

      Mr. Wild brings over 20 years of experience building profitable commercial organizations at leading healthcare brands Allurion Technologies, Inc. (NYSE:ALUR), a company dedicated to ending obesity, today announced the appointment of Adrian Wild as SVP, International Commercial. Effective August 13, 2024, Mr. Wild assumed the role and will lead the Company's international commercial sales and operations functions. "We are thrilled to welcome Adrian to Allurion and add his expertise to our leadership team as we advance the company toward profitability," said Dr. Shantanu Gaur, Allurion's Founder and CEO. "Adrian joins us at an extremely important time – where the obesity market is expandi

      8/20/24 8:00:00 AM ET
      $ALUR
      Medical/Dental Instruments
      Health Care
    • Allurion Announces the Appointment of Ojas A. Buch as Chief Operating Officer

      Allurion Technologies, Inc. (NYSE:ALUR), a company dedicated to ending obesity, today announced the appointment of Ojas A. Buch as its new Chief Operating Officer. Effective June 3, 2024, Ojas assumed the role of Chief Operating Officer and will lead the company's Research and Development, Manufacturing and Operations, Quality and Regulatory, and Business Development and Innovation functions. He will also play a crucial role in commercial functions while working closely with the Board and Executive Leadership Team. Ojas will provide strategic and execution-focused guidance aimed to help the company achieve major milestones and scale sustainably. With a 25-year track record in the health

      6/5/24 8:00:00 AM ET
      $ALUR
      Medical/Dental Instruments
      Health Care

    $ALUR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Allurion Technologies Inc.

      SC 13G/A - ALLURION TECHNOLOGIES, INC. (0001964979) (Subject)

      11/14/24 4:43:43 PM ET
      $ALUR
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Allurion Technologies Inc.

      SC 13G/A - ALLURION TECHNOLOGIES, INC. (0001964979) (Subject)

      11/14/24 4:15:52 PM ET
      $ALUR
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Allurion Technologies Inc.

      SC 13D/A - ALLURION TECHNOLOGIES, INC. (0001964979) (Subject)

      10/24/24 5:19:39 PM ET
      $ALUR
      Medical/Dental Instruments
      Health Care

    $ALUR
    Financials

    Live finance-specific insights

    See more
    • Allurion Reports First Quarter 2025 Financial Results and Provides Business Update

      Allurion Technologies, Inc. (NYSE:ALUR) ("Allurion" or the "Company"), a pioneer in metabolically healthy weight loss, today announced its financial results for the first quarter and provided a business update. Recent Company Highlights and Outlook Maintaining 2025 revenue guidance of approximately $30 million with a reduction of approximately 50% in operating expenses compared to 2024 First quarter revenue of $5.6 million and operating expenses of $11.4 million, a 37% decrease in operating expenses compared to prior year; adjusted operating expenses of $10.1 million, a 45% decrease compared to prior year Net operating loss of $7.3 million, a 36% reduction compared to prior year; adj

      5/14/25 8:00:00 AM ET
      $ALUR
      Medical/Dental Instruments
      Health Care
    • Allurion to Report First Quarter 2025 Financial Results on May 14, 2025

      Allurion Technologies, Inc. ("Allurion" or the "Company") (NYSE:ALUR), a company dedicated to ending obesity, today announced that it will report financial results for the first quarter 2025 on Wednesday, May 14, 2025. Company management will host a conference call to discuss financial results and provide a business update on the same day at 8:30 AM ET. To access the conference call by telephone, please dial (888) 330-3417 (domestic) or +1 646 960 0804 (international) and use Conference ID 1905455. To listen to the conference call via live audio webcast, please visit the Events section of Allurion's Investor Relations website at Allurion - Events & Presentations. A replay of the conferenc

      5/5/25 4:05:00 PM ET
      $ALUR
      Medical/Dental Instruments
      Health Care
    • Allurion Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update

      Allurion Technologies, Inc. (NYSE:ALUR) ("Allurion" or the "Company"), a company dedicated to ending obesity, today announced its financial results for the fourth quarter and full year ended December 31, 2024 and provided a business update. Recent Company Highlights and Outlook Reported initial data on the combination of the Allurion Program with low-dose GLP-1s showing optimization of muscle mass and GLP-1 adherence and announced plans to perform additional prospective studies on the combination approach Fourth quarter 2024 revenue of $5.6 million and full year revenue of $32.1 million, consistent with preannouncement on January 14, 2025 Fourth quarter 2024 operating expenses of $19

      3/26/25 8:00:00 AM ET
      $ALUR
      Medical/Dental Instruments
      Health Care